drugset
drugset / Trial / NCT04128579

Study of EQ001 (Itolizumab) in Systemic Lupus Erythematosus With or Without Active Proliferative Nephritis

NCT04128579 ↗

Phase 1 Completed 52 enrolled Biocon Limited
Non-randomizedSequentialOpen-labelTreatment

Summary

This is a multi-center study to evaluate the safety, tolerability, PK, PD, and clinical activity of itolizumab (EQ001) in subjects with Systemic Lupus Erythematosus with or without Active Proliferative Lupus Nephritis

Timeline

Start
2019-10-01
Primary completion
2023-11-16
Completion
2024-01-18

Drugs

EvaluationDrugModalityDoseRoute
Subject Itolizumab Monoclonal antibody 1.6 mg/kg Subcutaneous

Indications

lupus erythematosus lupus nephritis